Kevin Kunzmann

The 30-person panel, including physicians and patients, recommended a median 12.5 tablets of 5mg opioid for 20 common procedures.

A Denmark retrospective study of 7 million-plus individuals found associations between increased TBI severity and frequency, and suicide risk.

Chervenak was recently appointed chair of the department of obstetrics and gynecology at Lenox Hill Hospital and chair of the academic department of obstetrics & gynecology and associate dean for international medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

If approved in early 2019, the nasal spray would become the first approved therapy indicated for seizure clusters in 17 years.

The designation was based on data from 7 clinical trials over the past decade which assessed Xolair's efficacy and safety versus various food allergens such as peanut, milk, and egg.

Galafold differs from common enzyme replacement therapy in that it increases the activity of the body’s deficient enzyme.

Patisiran also makes history as the first FDA-approved small interfering ribonucleic acid treatment, a class of drugs that silences the portion of RNA involved in causing the disease.

Natural Cycles requires women enter a daily basal thermometer body temperature to detect minor rises in temperature at the time of ovulation. It also tracks the user’s menstrual cycle.

In a systematic review and meta-analysis, low-quality drugs are most prevalent low- to middle-income countries, and can cost up to $200 billion annually.

According to pooled data, 91.8% of the hospitalizations due to firearm injuries in pediatric and adolescent patients were of urban patients, 4.8% were of micropolitan patients, and 3.3% were of rural patients.

The novel methylphenidate formulation indicated for evening administration in patients with ADHD aged 6 years and older has shown improvement in the severity of ADHD symptoms in the early morning and throughout the day for patients.

Through Warrior Centric Health, the 25-year US Navy vet has bridged the gap between civilian physicians and the specific-need veterans left behind.

In a trio of phase 3 studies, omadacycline met the FDA-designated primary and secondary efficacy outcomes while reporting consistent safety measures and tolerability.

The REGENXBIO drug's promising phase 1 results has led to the addition of a fourth patient dosing cohort and a phase 2 trial initiation.

The oral therapy was previously approved for use in children aged 6 years and older with CF and 2 copies of the F508del-CFTR mutation, the most common genetic form of the disease.

Researchers were able to rule out myocardial infarction in 30% of patients immediately, and another 25% of patients at 1 hour. By 3 hours, the assay had successfully ruled out MI in 83.8% of patients, versus the 80.4% ruled out under the conventional assay.

How researchers are using stem cells and a greater patient population to improve on the invasive methods used to treat the common women's disease.

A qualitative narrative analysis of 300-plus submitted essays led to answers as to what factors contribute to inclusive environments at work or education institutions.

After a high-volume flu season driven by outbreak of the mutated H3N2 strain, Sanofi has bolstered its vaccine class with options specific to older populations.

The second member of the FDA-approved thrombopoietin receptor agonist drug class was proven efficacious and safe in a pair of phase 3 trials.

The 2 assays from Ortho Clinical Diagnosis consolidates the company's package of devices and systems designed to give patients frequent diagnoses.

The device supplants Abbott's own 10-day Libre system as the longest-lasting self-applied continuous glucose monitoring system on the US market.

The FDA accepted the NDA for NKTR-181, a drug with slowed entry into the brain that attenuates the dopamine release underlying euphoria.

How come treat-and-extend may not be the most ideal therapy regimen for retina disease, and how biologics change physicians' perspective on dosing.

Are anti-VEGF and PRP therapies the best-case scenario for patients with AMD, or will gene therapies reach the market in the near future?

How the three-year results of a gene therapy for inherited retinal disease may redefine its potential in ophthalmology.

A comparison of patients with either anterior segment neovascularization without glaucoma or neovascular glaucoma found the benefits of anti-VEGF and PRP are heavily influenced by the presence of glaucoma.

A three-year update of VN for patients with biallelic RPE65 mutation-associated inherited retinal disease improved on the common standard-of-care for retina disease.

Results from the PACORES group clinical trial debunked previously-held beliefs that IVB is unsafe for patients with proliferative diabetic retinopathy undergoing the procedure.

Why substantial evidence is lacking to indicate either therapy method's preference for the treatment of neovascularization.